The paper found that, while cannabis consumers have higher rates of psychotic experiences than non-consumers, the difference was indeed more pronounced among those with a high genetic predisposition to schizophrenia.
In a new meta-analysis of past cannabis impairment studies, researchers at the University of Sydney have identified a “window of impairment” following medium and high-dose cannabis use, during which users should avoid driving.
A new trial has directly compared the antidepressant effects of psilocybin with a more classical antidepressant, and found that the two are matched in their mood-altering potential.
Teens who frequently see billboard or storefront advertising for recreational cannabis products are more likely to use the drug weekly and to have symptoms of cannabis use disorder, according to new research.
Both the cannabis users and non-users showed similar resting heart rates and blood pressure levels, but the study’s authors are still concerned that even young cannabis consumers have an elevated risk of developing cardiovascular disease.
Drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular chemical twin.
According to the study, up to a third of supposedly CBD-dominant cannabis products sold in Massachusetts may not contain any CBD at all.
Blood tests are inherently flawed, research has shown, because they don’t indicate how long the THC has been in the system, the driver’s tolerance, how high they actually are or whether they are impaired at that moment.